In colorectal cancer, for instance, B-RAF inhibitors alone are ineffective due to EGFR reactivation, but the combination of B-RAF + MEK + EGFR inhibitors has demonstrated significant survival benefits, underscoring the necessity of combination regimens in certain tumor types [39]. The gene discussed is EGFR; the disease is neoplasm.